These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

529 related articles for article (PubMed ID: 30952982)

  • 1. Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours.
    Yao H; Lan J; Li C; Shi H; Brosseau JP; Wang H; Lu H; Fang C; Zhang Y; Liang L; Zhou X; Wang C; Xue Y; Cui Y; Xu J
    Nat Biomed Eng; 2019 Apr; 3(4):306-317. PubMed ID: 30952982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benzosceptrin C induces lysosomal degradation of PD-L1 and promotes antitumor immunity by targeting DHHC3.
    Wang Q; Wang J; Yu D; Zhang Q; Hu H; Xu M; Zhang H; Tian S; Zheng G; Lu D; Hu J; Guo M; Cai M; Geng X; Zhang Y; Xia J; Zhang X; Li A; Liu S; Zhang W
    Cell Rep Med; 2024 Feb; 5(2):101357. PubMed ID: 38237597
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Zhu Q; Wang H; Chai S; Xu L; Lin B; Yi W; Wu L
    Proc Natl Acad Sci U S A; 2023 Mar; 120(13):e2216796120. PubMed ID: 36943877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nafamostat mesilate, a serine protease inhibitor, suppresses interferon-gamma-induced up-regulation of programmed cell death ligand 1 in human cancer cells.
    Homma S; Hayashi K; Yoshida K; Sagawa Y; Kamata Y; Ito M
    Int Immunopharmacol; 2018 Jan; 54():39-45. PubMed ID: 29100036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treating ICB-resistant cancer by inhibiting PD-L1 via DHHC3 degradation induced by cell penetrating peptide-induced chimera conjugates.
    Shi YY; Fan G; Tan R; Li S; Sun HB; Li R; Yang M; Gao S; Liu M; Dai MY
    Cell Death Dis; 2024 Sep; 15(9):701. PubMed ID: 39349454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity.
    Burr ML; Sparbier CE; Chan YC; Williamson JC; Woods K; Beavis PA; Lam EYN; Henderson MA; Bell CC; Stolzenburg S; Gilan O; Bloor S; Noori T; Morgens DW; Bassik MC; Neeson PJ; Behren A; Darcy PK; Dawson SJ; Voskoboinik I; Trapani JA; Cebon J; Lehner PJ; Dawson MA
    Nature; 2017 Sep; 549(7670):101-105. PubMed ID: 28813417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity.
    Li CW; Lim SO; Xia W; Lee HH; Chan LC; Kuo CW; Khoo KH; Chang SS; Cha JH; Kim T; Hsu JL; Wu Y; Hsu JM; Yamaguchi H; Ding Q; Wang Y; Yao J; Lee CC; Wu HJ; Sahin AA; Allison JP; Yu D; Hortobagyi GN; Hung MC
    Nat Commun; 2016 Aug; 7():12632. PubMed ID: 27572267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Palmitoylation stabilizes PD-L1 to promote breast tumor growth.
    Yang Y; Hsu JM; Sun L; Chan LC; Li CW; Hsu JL; Wei Y; Xia W; Hou J; Qiu Y; Hung MC
    Cell Res; 2019 Jan; 29(1):83-86. PubMed ID: 30514902
    [No Abstract]   [Full Text] [Related]  

  • 9. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer.
    Mace TA; Shakya R; Pitarresi JR; Swanson B; McQuinn CW; Loftus S; Nordquist E; Cruz-Monserrate Z; Yu L; Young G; Zhong X; Zimmers TA; Ostrowski MC; Ludwig T; Bloomston M; Bekaii-Saab T; Lesinski GB
    Gut; 2018 Feb; 67(2):320-332. PubMed ID: 27797936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The deubiquitinase USP22 regulates PD-L1 degradation in human cancer cells.
    Wang Y; Sun Q; Mu N; Sun X; Wang Y; Fan S; Su L; Liu X
    Cell Commun Signal; 2020 Jul; 18(1):112. PubMed ID: 32665011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SA-49, a novel aloperine derivative, induces MITF-dependent lysosomal degradation of PD-L1.
    Zhang N; Dou Y; Liu L; Zhang X; Liu X; Zeng Q; Liu Y; Yin M; Liu X; Deng H; Song D
    EBioMedicine; 2019 Feb; 40():151-162. PubMed ID: 30711516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simultaneous blocking of CD47 and PD-L1 increases innate and adaptive cancer immune responses and cytokine release.
    Lian S; Xie R; Ye Y; Xie X; Li S; Lu Y; Li B; Cheng Y; Katanaev VL; Jia L
    EBioMedicine; 2019 Apr; 42():281-295. PubMed ID: 30878596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIP1R targets PD-L1 to lysosomal degradation to alter T cell-mediated cytotoxicity.
    Wang H; Yao H; Li C; Shi H; Lan J; Li Z; Zhang Y; Liang L; Fang JY; Xu J
    Nat Chem Biol; 2019 Jan; 15(1):42-50. PubMed ID: 30397328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intratumoral Delivery of an Adenoviral Vector Carrying the
    Nakagawa S; Serada S; Kakubari R; Hiramatsu K; Sugase T; Matsuzaki S; Matsuzaki S; Ueda Y; Yoshino K; Ohkawara T; Fujimoto M; Kishimoto T; Kimura T; Naka T
    Mol Cancer Ther; 2018 Sep; 17(9):1941-1950. PubMed ID: 29891489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpressed histone acetyltransferase 1 regulates cancer immunity by increasing programmed death-ligand 1 expression in pancreatic cancer.
    Fan P; Zhao J; Meng Z; Wu H; Wang B; Wu H; Jin X
    J Exp Clin Cancer Res; 2019 Feb; 38(1):47. PubMed ID: 30709380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of Glutamine Utilization Synergizes with Immune Checkpoint Inhibitor to Promote Antitumor Immunity.
    Byun JK; Park M; Lee S; Yun JW; Lee J; Kim JS; Cho SJ; Jeon HJ; Lee IK; Choi YK; Park KG
    Mol Cell; 2020 Nov; 80(4):592-606.e8. PubMed ID: 33159855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas.
    Goodman A; Patel SP; Kurzrock R
    Nat Rev Clin Oncol; 2017 Apr; 14(4):203-220. PubMed ID: 27805626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-L1 knockdown via hybrid micelle promotes paclitaxel induced Cancer-Immunity Cycle for melanoma treatment.
    Tang X; Rao J; Yin S; Wei J; Xia C; Li M; Mei L; Zhang Z; He Q
    Eur J Pharm Sci; 2019 Jan; 127():161-174. PubMed ID: 30366077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumour-activated neutrophils in gastric cancer foster immune suppression and disease progression through GM-CSF-PD-L1 pathway.
    Wang TT; Zhao YL; Peng LS; Chen N; Chen W; Lv YP; Mao FY; Zhang JY; Cheng P; Teng YS; Fu XL; Yu PW; Guo G; Luo P; Zhuang Y; Zou QM
    Gut; 2017 Nov; 66(11):1900-1911. PubMed ID: 28274999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maprotiline Prompts an Antitumour Effect by Inhibiting PD-L1 Expression in Mice with Melanoma.
    Liang L; Li Y; Jiao Y; Zhang C; Shao M; Jiang H; Wu Z; Chen H; Guo J; Jia H; Zhao T
    Curr Mol Pharmacol; 2024; 17(1):e18761429259562. PubMed ID: 37982288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.